Navigation Links
Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
Date:9/18/2008

BOSTON, Sept. 18 /PRNewswire/ -- Scimitar Equity, LLC issues a Q4/08 review of Neurobiological Technologies, Inc. (Nasdaq: NTII), entitled, "Defining Outcome Scenarios, Probabilities Appear Focused to the Upside and Future Appreciation." This review is available at our website: http://www.scimitarequity.com

Neurobiological Technologies, Inc. (NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. NTII is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. Neurobiological Technologies, Inc. is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. For further information, please visit NTII's website at http://www.ntii.com

Scimitar Equity, LLC provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about NTII (NASDAQ) and its or their securities. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.

CONTACT:

Scimitar Equity, LLC

Henry W. McCusker

Director of Research

phone: (617) 559.1080

e-mail: hwm@scimitarequity.com


'/>"/>
SOURCE Scimitar Equity, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
2. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
3. Neurobiological Technologies CEO to Retire on December 31, 2008
4. Neurobiological Technologies Reports Third Quarter Financial Results
5. Neurobiological Technologies Sets Date for Third Quarter Financial Results
6. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
7. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
8. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
9. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
10. Neurobiological Technologies Sets Date for Research and Development Day
11. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 11, 2019 , ... Mytonomy, the leader in ... in opioid treatment, announced today they are partnering to combat the opioid crisis ... its virtual care platform at the Mayo Clinic to drive shared decision making ...
(Date:5/31/2019)... (PRWEB) , ... May 29, 2019 , ... For many ... the toughest forms of cancer demand breakthrough therapies. Advances in immuno-oncology have led to ... patient’s own T cells with engineered T cell receptors known as “CARs”. The CAR ...
(Date:5/31/2019)... , ... May 30, 2019 , ... ... first to demonstrate an efficient delivery system for the sustained release of human ... platelet-rich plasma-based gel system was able to deliver CM into the injured kidney, ...
(Date:5/15/2019)... ... 16, 2019 , ... Emulsifiers are the magic bullet when ... rely on these ingredients to create stable quality food that can withstand shelf-life ... triggers food formulators to seek out alternatives for starches, gums and chemical emulsifiers. ...
Breaking Biology Technology:
(Date:5/31/2019)... (PRWEB) , ... May 29, 2019 , ... ... configurations on Mac, Windows and mobile, announces the launch of version 13.1. The ... the latest Android Management API, and supports Apple’s spring release functionality. Version 13.1 ...
(Date:5/31/2019)... ... 30, 2019 , ... Join Julie Peacock, Vice President of ... Wednesday, June 19, 2019 at 1pm EDT where she will demonstrate how role-based ... and contract research organizations (CROs) can improve collaboration, auditing, document tracking and reporting. ...
(Date:5/31/2019)... HOUSTON (PRWEB) , ... May 31, 2019 , ... ... at the Houston Marriott Westchase in Houston, TX, announced today that Ben Reiter, ... address on the afternoon of Wednesday, October 3rd.     , Reiter predicted the Houston ...
Breaking Biology News(10 mins):